Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 425, 174-182
Abstract
No abstract availableKeywords
Funding Information
- University of Oklahoma Health Sciences Center
This publication has 37 references indexed in Scilit:
- Purine Nucleoside Phosphorylase Targeted by Annexin V to Breast Cancer Vasculature for Enzyme Prodrug TherapyPLOS ONE, 2013
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysisGynecologic Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Enzyme prodrug therapy designed to target l-methioninase to the tumor vasculatureCancer Letters, 2011
- Ovarian Cancer Development and MetastasisThe American Journal of Pathology, 2010
- Methylselenol generated from selenomethionine by methioninase downregulates integrin expression and induces caspase‐mediated apoptosis of B16F10 melanoma cellsJournal of Cellular Physiology, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- PEGylation Confers Greatly Extended Half-Life and Attenuated Immunogenicity to Recombinant Methioninase in PrimatesCancer Research, 2004
- Circulating Half-Life of PEGylated Recombinant Methioninase Holoenzyme Is Highly Dose Dependent on Cofactor Pyridoxal-5′-PhosphateCancer Research, 2004
- Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cellsCancer Gene Therapy, 2003